LDL-C Reduction in the Patient with Diabetes: How Low Should We Go and How Should We Get There?

The major cause of death and complications in patients with type 2 diabetes is due to cardiovascular disease (CVD). More than 60% of all patients with type 2 diabetes die of CVD, and a greater percentage will have major adverse cardiovascular events. Dyslipidemia, one of the major risk factors associated with atherosclerotic CVD, is highly prevalent in type 2 diabetes, and, along with genetic abnormalities of LDL-C such as familial hypercholesterolemia, constitutes a key target for aggressive therapy. Statins are highly effective in lowering LDL-C levels and represent first-line treatment for prevention of CVD. For nearly two decades, statin use has been a cornerstone of CVD management. The 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults essentially codified the use of statin therapy in patients at risk for cardiovascular events and stroke. Other guidelines have also endorsed the use of statins as first-line therapy, but continue to use quantitative lipid targets as treatment goals. However, despite these recommendations increasing the pool of eligible patients, many will either not take statins due to off-target effects or require intensification of therapy to avoid residual CVD risk. This requires clinicians to examine the latest data on lipid reduction and potential changes in risk reduction strategies, particularly for those at high risk of CVD and its adverse sequella.


Please Note: this course is housed on Real CME. Upon selecting 'Take Course,' you will be redirected to Real CME to compete the activity.

Target Audience

Endocrinologists, Diabetologists, Diabetes Educators, Internists, Clinical Cardiologists, Geriatricians, Nurse Practitioners, Physician Assistants, and other healthcare providers who care for patients with type 2 diabetes and patients with hyperlipidemia.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Identify the major clinical issues in the management of dyslipidemia in patients with diabetes
  2. Recognize major benefits and limitations of statin and other add-on therapies to modulate LDL-C in reaching target goals
  3. Discuss the interrelationship between dyslipidemia and diabetes
  4. Appreciate the potential of PCSK9 inhibition and other therapeutic modalities to improve the management of patients with dyslipidemia
  5. Use the latest evidence and guidelines to optimize management of patients with diabetes and dyslipidemia
Additional information
Available for MOC Points?: 
No
Course summary
Available credit: 
  • 1.75 AMA
  • 1.75 Attendance
Course opens: 
07/21/2016
Course expires: 
07/21/2017
Cost:
$0.00

Yehuda Handelsman, MD, FACP, FACE, FNLA; Robert Eckel, MD; Sergio Fazio, MD, PhD, FAAP, FASCI

Available Credit

  • 1.75 AMA
  • 1.75 Attendance

Accreditation Period

Course opens: 
07/21/2016
Course expires: 
07/21/2017

Price

Cost:
$0.00
Please login or register to take this course.